SUBSCRIBE
SUBSCRIBE
News   Drug Development

Peptech Limited Successfully Completes Phase I Trial for PN0621

October 29, 2007 | 
1 min read

29 October 2007 Sydney, Australia: Biopharmaceutical company, Peptech Limited (ASX: PTD, AIM: PTDx) today announced the completion of the Phase I trial of its lead compound for rheumatoid arthritis PN0621.

Clinical research Phase I Australia
MORE ON THIS TOPIC
Funding
Nuvig Ropes in $161M Series B From Big Pharma Players for Autoimmune Indications
December 5, 2024
 · 
1 min read
 · 
Kate Goodwin
Handshake gesture contemporary collage art. Celebrating success, congratulating for financial and business partnership, job contract deal, mutual friendship and respect. Abstract illustration isolated.
Alzheimer’s disease
GSK Strikes Third Agreement This Week, Leans Further Into Neuro
December 5, 2024
 · 
2 min read
 · 
Tristan Manalac
GSK's headquarters office building in Poznan, Poland
ADCs
GSK Turns Back to China in Another Potential $1B+ ADC Deal
December 4, 2024
 · 
1 min read
 · 
Kate Goodwin
Crowdfunding concept with money icon and human hands in retro 80s collage mixed media vector illustration. Idea for financing business project, funding, philanthropy, cooperation, bank credit and startup development.
Series A
Obesity-Focused Antag Debuts With $84M and Backing From Novo Holdings
December 4, 2024
 · 
2 min read
 · 
Heather McKenzie